

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/583,585	Applicant: Glen Ernst, et al.
Filing Date: April 10, 2007	Attorney Docket No.: 101333-1P US
Examiner: Douglas M. Willis	Group Art Unit : 1614
Customer No.: 22466	Confirmation No.: 1463
Title: Nicotinic Acetylcholine Receptor Ligands	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

No English version of NL Patent No. 6501367 is available. For the convenience of the Examiner Applicants list a copy of US Patent No. 3281423 that is the US equivalent of NL Patent No. 6501367.

### **REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114.

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to Deposit Account No. 260166, referencing Attorney Docket No. 101333-1P US.

Respectfully submitted,

/ Michael A. Patané /

---

Name: Michael A. Patané

Dated: October 9, 2008  
Reg. No.: 42,982  
Phone No.: 302.885.3948  
Global Intellectual Property, Patents,  
AstraZeneca,  
1800 Concord Pike,  
Wilmington, DE 19850-5437